Taxotere is a chemotherapy agent that was put on the market in 1996 to treat breast cancer. Since that time, its approved use has expanded to include various other types of cancer, such as head and neck cancer, gastric cancer, prostate cancer, and non-small cell lung cancer.
Of course, hair loss is a common side effect of chemotherapy. However, in the United States, the manufacturer, Sanofi-Aventis, only warned that hair loss would be temporary and that hair generally grows back. While it was making these representations to patients in the United States, many of whom are women, Sanofi Aventis advised authorities, patients, and physicians in the European Union and Canada that Taxotere causes an increased risk of permanent, disfiguring hair loss.
In December 2015, armed with patients complaints and truthful information, the FDA forced Sanofi-Aventis to update the label to warn of the risk of permanent hair loss. Unfortunately for many patients, this came too late. Had they been armed with this information up front, they could have made the decision to treat with other, equally effective chemotherapy treatments. Studies have shown that people strongly associate their hair with a positive self-image and positive self-esteem, the loss of which can have serious psychological and social consequences.
Holland Law Firm, a leading pharmaceutical drug and medical device firm, is investigating lawsuits on behalf of patients who suffered hair loss as a result of using Taxotere. Please call 877-255-3352 to speak with one of our lead attorneys to determine if you may be entitled to a recovery. You can also complete the information below and we will contact you.